Orthos Europe has been acquired by Atrium Innovations
September 2008 — Holland Venture has sold Orthos Europe to Atrium Innovations.
Orthos Europe’s main brand is AOV under which high-quality food supplements such as multi-vitamins, minerals, probiotics, enzymes, fatty acids and antioxidants are developed and marketed. The company was founded over 20 years ago and has a very strong position in the Netherlands, where it is a leading player in its market segment.
Atrium Innovations is a developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. Atrium markets a portfolio of finished products through its sales and marketing network in more than 35 countries, primarily in North America and Europe.
Holland Venture is an independent private equity fund located in Amsterdam. Since 1981, Holland Venture has realized the growth potential of many of its investments and has proven to be a trustworthy partner.
Our role in the transaction
Oaklins' team in the Netherlands advised the seller in this transaction.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more